Literature DB >> 23759252

Poliovirus vaccination options for achieving eradication and securing the endgame.

Concepción F Estívariz1, Mark A Pallansch, Abhijeet Anand, Steven G F Wassilak, Roland W Sutter, Jay D Wenger, Walter A Orenstein.   

Abstract

In 1988, the World Health Assembly resolved to globally eradicate poliomyelitis. As part of a four-pronged strategy with establishment of enhanced surveillance, institution of national immunization days, strengthening routine immunization, and carrying-out mopping-up activities, oral poliovirus vaccine (OPV) was selected as the vaccine-of-choice for eradication. Massive OPV use decreased the number of polio-endemic countries from >125 countries in 1988 to only 3 in 2012 and led to a >99.9% decrease in polio incidence in the corresponding period. In this communication, we will discuss polio vaccination options to accelerate eradication, to mitigate the risks during the planned withdrawal of type 2 OPV, and to secure eradication for future generations. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23759252     DOI: 10.1016/j.coviro.2013.05.007

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  23 in total

1.  Introduction of sequential inactivated polio vaccine-oral polio vaccine schedule for routine infant immunization in Brazil's National Immunization Program.

Authors:  Carla Magda Allan S Domingues; Sirlene de Fátima Pereira; Ana Carolina Cunha Marreiros; Nair Menezes; Brendan Flannery
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

2.  Maximising the impact of inactivated polio vaccines.

Authors:  Elizabeth B Brickley; Peter F Wright
Journal:  Lancet Infect Dis       Date:  2017-04-25       Impact factor: 25.071

Review 3.  Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

Authors:  Heidi Barth
Journal:  World J Hepatol       Date:  2015-04-18

4.  Effect of formaldehyde inactivation on poliovirus.

Authors:  Thomas Wilton; Glynis Dunn; David Eastwood; Philip D Minor; Javier Martin
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

5.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

Authors:  David Escors
Journal:  New J Sci       Date:  2014-01-05

6.  Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque.

Authors:  Chris Edens; Naomi C Dybdahl-Sissoko; William C Weldon; M Steven Oberste; Mark R Prausnitz
Journal:  Vaccine       Date:  2015-03-03       Impact factor: 4.169

7.  Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.

Authors:  Jes Dietrich; Lars Vibe Andreasen; Peter Andersen; Else Marie Agger
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

8.  First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.

Authors:  Line M Lindgren; Pernille N Tingskov; Annette H Justesen; Bettina S Nedergaard; Klaus J Olsen; Lars V Andreasen; Ingrid Kromann; Charlotte Sørensen; Jes Dietrich; Birgit Thierry-Carstensen
Journal:  Vaccine       Date:  2016-12-24       Impact factor: 3.641

Review 9.  Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

Authors:  Edward Pk Parker; Natalie A Molodecky; Margarita Pons-Salort; Kathleen M O'Reilly; Nicholas C Grassly
Journal:  Expert Rev Vaccines       Date:  2015-07-09       Impact factor: 5.217

Review 10.  Eradication and Current Status of Poliomyelitis in Pakistan: Ground Realities.

Authors:  Shazia Ghafoor; Nadeem Sheikh
Journal:  J Immunol Res       Date:  2016-07-18       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.